TABLE 1

A. nancymaae demographicsa

Study Vaccineb
(no. of doses)
Primary challenge
strain (dose, CFU)
Demographic variable
No. of animalsNo. of males/no. of femalesMean age, moc (SD)Mean weight, gc (SD)
Challenge (dose finding)NAH10407 (8.0 × 109)53/259.8 (7.97)1,338 (111.4)
H10407 (5.1 × 1010)52/360.1 (17.53)1,332 (272.9)
H10407 (5.8 × 1011)52/350.7 (5.605)1,482 (185.2)
Challenge (dose confirmation)NAH10407 (7.5 × 1011)105/538.8 (16.04)1,298 (139)
H10407-P (6.4 × 1011)54/153.4 (1.171)1,230 (70.71)
HS (7.9 × 1011)52/352.1 (0.6993)1,330 (201.2)
Vaccination/challenge
(expt 1)
dscCfaE (4)H10407 (5.0 × 1011)104/619.91 (5.882)900 (146.4)
dscCfaE+CTB (4)H10407 (5.0 × 1011)105/521.15 (5.305)828 (128.7)
PBS (4)H10407 (5.0 × 1011)105/522.24 (14.63)899 (183.8)
Vaccination/challenge
(expt 2)
dscCfaE+LTB (4)H10407 (5.4 × 1011)82/631.34 (5.761)917.5 (80.84)
dscCfaE+LTB (3)H10407 (5.4 × 1011)85/330.31 (3.909)1,086d (242.5)
PBS (4)H10407 (5.4 × 1011)85/336.96 (13.38)943.8 (154.5)
Vaccination/challengee
(expt 3)
dscCfaE+LTB (4)H10407 (5.3 × 1011)103/729.93 (10.55)
PBS (4)H10407 (5.3 × 1011)108/225.09 (4.415)
  • a Gender, age, and weight data are shown separately for each study.

  • b All vaccine antigens were administered intranasally; for all vaccinations, doses of 0.2 mg dscCfaE and 0.29 mg adjuvant were given. NA, not applicable.

  • c Age and weight data collected on day 0 except where noted.

  • d Data for this group reflect weights collected prior to the first vaccination on day 56; data were collected on 5 of the 8 animals.

  • e Weight data not available for these groups.